Shots:
- The US FDA has granted full approval to Vetmedin chewable tablets (pimobendan) & Vetmedin oral solution for the delay of onset of CHF in dogs with Stage B2 preclinical myxomatous mitral valve disease (MMVD)
- Approval was based on the 2 multi-site studies, with the EPIC trial showing Vetmedin delayed CHF onset or cardiac-related death by 15.6mos. vs control in dogs with Stage B2 preclinical MMVD, & a second study showing 79% remained CHF-free after 1yr.
- Adding a new indication to the Vetmedin label, the approval complements its use in managing mild to severe CHF in dogs with MMVD or dilated cardiomyopathy alongside standard therapies, with studies showing improved survival & QoL
Ref: PRnewswire | Image: BI  | Press Release
Related News: Boehringer Ingelheim Secures CVMP Positive Opinion for Vaxxitek HVT+IBD+H5 and Vaxxinact H5 Vaccines Against Avian Influenza
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
